Compounds

Details Compounds Compounds

2008-04-29

2011-10-11

Carr, Deborah D (Department: 1622)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Radical -xh acid, or anhydride, acid halide or salt thereof...

C554S163000, C554S224000

Reexamination Certificate

active

08034842

ABSTRACT:
Compounds of formula (I);whereinR1and R2are the same or different and may be selected from the group consisting of a hydrogen atom, a hydroxy group, an alkyl group, a halogen atom, an alkoxy group, an acyloxy group, an acyl group, an alkenyl group, an alkynyl group, an aryl group, an alkylthio group, an alkoxycarbonyl group, an alkylsulfinyl group, an alkylsulfonyl group, an amino group, and an alkylamino group; andX represents a carboxylic acid group, a carboxylate group, or a carboxamide group;or any pharmaceutically acceptable salt, solvate, complex or pro-drug thereof, with the provisos that the compound of formula (I) is not (all-Z)-4,7,10,13,16,19-docosahexaenoic acid (DHA), alpha-methyl-DHA, alpha-methyl DHA methyl ester, alpha-methyl-DHA ethyl ester or alpha-hydroxy DHA ethyl ester, are disclosed.A fatty acid composition and a pharmaceutical composition comprising such compounds are also disclosed. The use of such compounds as medicaments, in particular for the treatment of diabetes type 2, is also disclosed.

REFERENCES:
patent: 4132719 (1979-01-01), Mohrbacher et al.
patent: 4264517 (1981-04-01), Liang
patent: 4647685 (1987-03-01), Bonjouklian et al.
patent: 5502077 (1996-03-01), Breivik et al.
patent: 5656667 (1997-08-01), Breivik et al.
patent: 5698594 (1997-12-01), Breivik et al.
patent: 6365628 (2002-04-01), Berge
patent: 6689812 (2004-02-01), Peet et al.
patent: 7550613 (2009-06-01), Bryhn et al.
patent: 2004/0162348 (2004-08-01), Peet et al.
patent: 2006/0135610 (2006-06-01), Bortz et al.
patent: 1 300 470 (2003-04-01), None
patent: 1 310 249 (2003-05-01), None
patent: 1 426 047 (2004-06-01), None
patent: 1 466 597 (2004-10-01), None
patent: 1 544 281 (2005-06-01), None
patent: 05-000974 (1993-01-01), None
patent: 06-240289 (1994-08-01), None
patent: 10-195023 (1998-07-01), None
patent: 2003-283858 (2005-02-01), None
patent: WO 97/44063 (1997-11-01), None
patent: WO 02/052955 (2002-07-01), None
patent: WO 03/092673 (2003-11-01), None
patent: WO 2004/012727 (2004-02-01), None
patent: WO 2004/043894 (2004-05-01), None
patent: WO 2004/078166 (2004-09-01), None
patent: WO 2004/085582 (2004-10-01), None
patent: WO 2005/060954 (2005-07-01), None
patent: WO 2006/117664 (2006-11-01), None
patent: WO 2006/117668 (2006-11-01), None
patent: WO 2007/107869 (2007-09-01), None
English Translation of JP 2003-283858.
English abstract of JP 05-000974.
English abstract of JP 10-195023.
English abstract of JP 06-240289.
Flock, Solveig, et al. “Syntheses of Some Polyunsaturated Sulfur and Oxygen—containing Fatty Acids Related to Eicosapentaenoic and Docosahexaenoic Acids”Acta Chemica Scandinavica(1999) 53:436-445.
Larsen, Laila, et al. “Sulfur-Substituted and α-Methylated Fatty Acids as Peroxisome Proliferator-Activated Receptor Activators”Lipids(2005) 40(1):49-57.
Office Action dated Jul. 24, 2008, from U.S. Appl. No. 11/417,252.
Office Action dated Nov. 29, 2007, from U.S. Appl. No. 11/417,252.
Vaagenes, Hege et al. “Methylated Eicosapentaenoic Acid and Tetradecylthioacetic Acid: Effects on Fatty Acid Metabolism”Biochemical Pharmacology(1999) 58:1133-1143.
Berger, A. et al., “Structural Requirements of Sphingosylphosphocholine and Sphingosine-1-phosphate for Stimulation of Activator Protein-1 Activity,”Molecular Pharmacol.(1996) 50:451-457.
Bonjouklian, R. et al., “Studies of the Antitumor Activity of (2-Alkoxyalkyl)- and (2-Alkoxyalkenyl)phosphocholines,”J. Med. Chem.(1986) 29:2472-2477.
CAPlus Abstract for Kaufmann, H. P. and Kirschnek, A., “Fatty aldehydes. IV. Preparation of fatty aldehydes containing more than one double bond,”Fette, Seifen, Anstrichmittel(1958) 60:1125-1132.
CAPlus Abstract, AN 1996:483717, for Kuklev, D. V., et al., “Synthesis of C2-elongated polyunsaturated fatty acids,”Bioorganischeskaya Khimiya(1996) 22(3):219-222.
Cateni, F. et al., “Total Synthesis of a Natural Cerebroside from Euphorbiaceae,”Helv. Chim. Acta(2007) 90:282-290.
Combs, Colin K., et al., “Inflammatory Mechanisms in Alzheimer's Disease: Inhibition of β-Amyloid-Stimulated Proinflammatory Responses and Neurotoxicity by PPARγ Agonists,”The Journal of Neuroscience(2000) 20(2):558-567.
Copending U.S. Appl. No. 12/446,249, filed Apr. 20, 2009.
Copending U.S. Appl. No. 12/446,615, filed Apr. 22, 2009.
Copending U.S. Appl. No. 12/447,092, filed Apr. 24, 2009.
Copending U.S. Appl. No. 12/740,377, filed Apr. 29, 2010.
Eichelberger, U. et al., “Synthesis of analogues of the 2-O-alkyl glycerate part of the moenomycins,”Tetrahedron(2002) 58:545-559.
Granlund, L. et al., “Effects of structural changes of fatty acids on lipid accumulation in adipocytes and primary hepatocytes,”Biochimica et Biophysica Acta(2005) 1687:23-30.
International Search Report for PCT/IB2007/003305 (U.S. Appl. No. 12/446,615) dated Mar. 20, 2008.
International Search Report for PCT/IB2007/004588 (U.S. Appl. No. 12/447,092) dated Nov. 21, 2008.
International Search Report for PCT/IB2007/004613 (U.S. Appl. No. 12/446,249) dated Apr. 16, 2009.
International Search Report for PCT/IB2008/003666 (U.S. Appl. No. 12/740,377) dated May 24, 2009.
Itoh, T. et al., “Synthesis of docosahexaenoic acid derivatives designed as novel PPARγ agonists and antidiabetic agents,”Bioorganic&Med. Chem.(2006) 98-108.
Kato, T. et al., “Abnormal Catabolites of Unsaturated Fatty Acids by In Vitro Reaction of Crude Enzyme from Infected Higher Plants,”Chem. Lett.(1994) 4:761-762.
Kaufmann, H. P. and Kirschnek, A., “Fatty aldehydes. IV. Preparation of fatty aldehydes containing more than one double bond,”Fette, Seifen, Anstrichmittel(1958) 60:1125-1132.
Kinsho, T. and Mori, K., “Synthesis of 3-Deoxy Analogs of Sphingolipids,”Agric. Biol. Chem.(1989) 53(10):2785-2790.
Kuklev, D. V., et al., “Synthesis of C2-elongated polyunsaturated fatty acids,”Bioorganischeskaya Khimiya(1996) 22(3):219-222.
Larsen, L. N. et al., “α- and β- Alkyl-Substituted Eicosapentaenoic Acids: Incorporation into Phospholipids and Effects on Prostaglandin H Synthase and 5-Lipoxygenase”Biochemical Pharmacology(1998) 55(4):405-411.
Magrioti, V. et al., “Synthesis and In Vivo Anti-Inflammatory Activity of Long-chain 2-Amino-alcohols,”Bioorg.&Med. Chem. Lett.(2003) 13:375-377.
Mangold, H. K., “Syntheses of Unsaturated Fatty Aldehydes,”J. Org. Chem.(1959) 24:405-407.
Meyer A. et al., “Biosynthesis of Docosahexaenoic Acid inEuglena gracilis: Biochemical and Molecular Evidence for the Involvement of a Δ4-Fatty Acyl Group Desaturase”Biochemistry(2003) 42(32):9779-9788.
Nishikawa, M. et al., “Low-calorie omega-3 fatty acid glyceride health food,” Database CAPLUS Chemical Abstracts XP002518330, STN Database Accession No. 2002:480253.
Pfeffer, P. E. et al., “α Anions of Carboxylic Acids. V. A Simple High Yield Presentation of α-Alkylhydracrylic Acids and α-Alkylacrylic Acids,”J. Org. Chem.(1972) 37(8):1256-1258.
Sinha, S. C. and Keinan, E., “Total Synthesis of (+)-Aspicilin. The Naked Carbon Skeleton Strategy vs the Bioorganic Approach,”J. Org. Chem.(1997) 62:377-386.
Tockizawa, K. et al., “Effects of phospholipids containing docosahexaenoic acid on differentiation and growth of HL-60 human promyelocytic leukemia cells,”J. Jpn. Oil Chem. Soc.(1997) vol. 46, pp. 383-390.
Vaagenes, H. et al., “Low Doses of Eicosapentaenoic Acid, Docosahexaenoic Acid, and Hypolipidemic Eicosapentaenoic Acid Derivatives Have No Effect on Lipid Peroxidation in Plasma”Lipids(1998) 33(11):1131-1137.
van der Linde, R. et al., “Synthesis of 2-substitutedcis-8,cis-11,cis-14-eicosatrienoic acids, precursors for 2-substituted prostaglandins,”J. Royal Netherlands Chem. Soc.(1975) 94(12):257-261.
Van Dorp, D. A. “Essential Fatty Acids and Prostaglandins,”Acta Biologica et Medica Germ

Affiliated with

Also associated with

Rating

Compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4266925